Shikari® (S-ATC) Anti-Cetuximab ELISA
Enzyme immunoassay for the qualitative determination of specific antibodies to Cetuximab (Erbitux®) in human serum and plasma.
This kit has been especially developed for the qualitative determination of Cetuximab in serum and plasma samples.
Cetuximab was associated to the development of anti- Cetuximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug. This might lead to severe complications. The Matriks Biotek SHIKARI® Antibody to Cetuximab ELISA Kit can be efficiently used for monitoring anti- Cetuximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti- Cetuximab antibodies.. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact firstname.lastname@example.org
|Required Volume (µl)||20|
|Total Time (min)||140|
|Detection Limit (ng/mL)||+/-|
|Spike Recovery (%)||-|
|Shelf Life (year)||1|
|Storage conditions||Store at +4°C. Please refer to protocols.|
|Shipping conditions||At room temperature|
|Instructions For Use||Download|
|Safety Data Sheet (SDS)||Download|
Publications with this drug
|Peña-Cabia, Silvia, et al. "Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer." Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 46.1 (2021): 21-26.||Visit Link|
|Zhang, Jinhua, et al. "sRNA-based screening chromosomal gene targets and modular designing Escherichia coli for high-titer production of aglycosylated immunoglobulin G." ACS Synthetic Biology (2020).||Visit Link|
|Zhang, Jinhua, et al. "Synthetic sRNA‐based Engineering of Escherichia coli for Enhanced Production of Full‐length Immunoglobulin G." Biotechnology Journal (2020): 1900363.||Visit Link|
|Kaito Shibata, et al. Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin Journal of Pharmaceutical and Biomedical Analysis Volume 146, Pages 266-272, 30 November 2017||Visit Link|
|Evaluación de la relación exposición-respuesta de bevacizumab y de cetuximab en cáncer colorrectal metastásico y de cetuximab en cáncer de cabeza y cuello Silvia Peña Cabia||Visit Link|